Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Blue Mesa Health

- PMLiVE

Novo Nordisk’s insulin icodec shows promise as once-weekly type 2 diabetes treatment

Currently, the basal insulin products with the longest duration are injected once daily

Women's health brand opportunities infographic

Women turn to brands for health advice after feeling sidelined by professionals

Women want brands to provide more health information, representing huge opportunities for brands to advocate for their consumers.

Thrive Agency

Biotech Innovation in the Time of COVID-19

Chris Garabedian, CEO of Xontogeny, dives into biotech and digital health innovation, current industry gaps and obstacles, how to encourage biotech entrepreneurs, AI & machine learning, and much more!

Impetus Digital

- PMLiVE

Merck granted fast track designation by FDA for end-stage renal disease therapy

MK-2060 is currently being investigated in a phase 2 study to evaluate the efficacy and safety of two different doses

- PMLiVE

Merck and Orna agree on deal worth $3.5bn for RNA technology

The companies will work together to develop proprietary circular RNA technology

- PMLiVE

AstraZeneca and Merck’s Lynparza combination therapy receives FDA priority review in first-line prostate cancer

Prostate cancer is the second most common cancer in male patients in the US, projected to cause around 35,000 deaths in 2022

Helping children with technology

The communication challenge of helping he next generation to be healthier

As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...

Page & Page and Partners

DEMOCRATISATION OF HEALTHCARE

Are we losing sight of what the democratisation of healthcare really looks like?

We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?

Page & Page and Partners

- PMLiVE

AstraZeneca and Daiichi Sankyo announce results for lung cancer therapy

Initial results for the combination therapy – with Merck’s Keytruda – show an overall response rate of 37% in patients with non-small cell lung cancer

- PMLiVE

Merck and Cerevance to research novel targets in Alzheimer’s disease

The total value of the deal is expected to be around $1.1bn

- PMLiVE

Merck and Cerevance to research novel targets in Alzheimer’s disease

The total value of the deal is expected to be around $1.1bn

- PMLiVE

TECHNOLOGY TRENDS AND THE FUTURE OF MEDICAL DEVICES

A MEDSCAPE DIGITAL HEALTH AND INNOVATION EVENT

Medscape Education Global

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links